Successful treatment with ceritinib after crizotinib induced hepatitis

Lung Cancer. 2016 May:95:15-6. doi: 10.1016/j.lungcan.2016.02.008. Epub 2016 Feb 23.

Abstract

We report two cases of acute hepatitis induced by crizotinib in patients with ALK-rearranged non-small cell lung cancer (NSCLC) who were treated after by a second generation of ALK inhibitor without any incident. These cases suggest that ceritinib could be used as an alternative agent when crizotinib is responsible for hepatitis.

Keywords: Anaplastic lymphoma kinase (ALK); Ceritinib; Crizotinib; Hepatitis; Non-small-cell-lung-cancer (NSCLC).

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / complications*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Crizotinib
  • Drug Substitution*
  • Female
  • Hepatitis / diagnosis
  • Hepatitis / etiology*
  • Humans
  • Lung Neoplasms / complications*
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / adverse effects*
  • Pyridines / adverse effects*
  • Pyrimidines / therapeutic use*
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • Sulfones / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Pyrimidines
  • Sulfones
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
  • ceritinib